Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Vertex's medication, named Journavx, is seen as a major development in the ongoing effort to provide effective pain management solutions without the harmful consequences associated with opioid ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

For decades, Americans struggling with pain had two options to find relief: over-the-counter medication such as ibuprofen, which often provided limited reprieve, or prescription opioids, and the ...

Journavx (suzetrigine), made by Vertex ... meeting a "major unmet need," noted Jianguo Cheng, MD, PhD, a pain management specialist at Cleveland Clinic. "This is the first time in nearly two ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

Arbuckle claims, as industry executives often do, that his team has had fruitful conversations with these stakeholders, that they appreciate Journavx may fill a major gap in pain management.

Evidence suggests that Journavx doesn't pose a risk of addiction as opioid medications do, making it a potentially safer alternative for pain management. "A new therapeutic class of non-opioid ...

"This action and the agency’s designations to expedite the drug’s development and review underscore FDA’s commitment to approving safe and effective alternatives to opioids for pain management.” ...

Vertex's Chronic Pain Ambitions Hit Roadblock with LSR Data So much of Journavx's potential lies in chronic pain management. In December, Vertex revealed Phase 2 data evaluating Journavx in ...

“With the approval of Journavx, a non-opioid ... we have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” Vertex’s chief executive ...

[Journavx] may help prevent the transition to chronic pain, reducing the need for long-term pain management strategies,” he said. Learn more about Journavx in the YouTube clip below.